Despite similar availability of diagnostic technologies to women of different racial and ethnic groups, significant disparities were seen in who actually received same-day diagnostic services and biopsies after abnormal mammogram findings, new research shows.
Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial
Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts